Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

PubWeight™: 2.80‹?› | Rank: Top 1%

🔗 View Article (PMID 16453327)

Published in Ann Neurol on March 01, 2006

Authors

Brian G Weinshenker1, Dean M Wingerchuk, Sandra Vukusic, Linda Linbo, Sean J Pittock, Claudia F Lucchinetti, Vanda A Lennon

Author Affiliations

1: Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. weinb@mayo.edu

Articles citing this

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64

Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28

AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79

Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology (2009) 1.78

MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology (2015) 1.74

Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68

Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis (2012) 1.61

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60

A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58

Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38

NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology (2009) 1.38

Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology (2012) 1.34

Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica. Nat Rev Neurol (2011) 1.30

Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol (2015) 1.26

The history of neuromyelitis optica. J Neuroinflammation (2013) 1.25

AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm (2014) 1.17

Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol (2007) 1.17

Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology (2007) 1.16

Familial neuromyelitis optica. Neurology (2010) 1.14

Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int (2012) 1.10

Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol (2010) 1.10

New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09

Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol (2010) 1.08

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry (2016) 1.08

Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci (2015) 1.07

An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. PLoS One (2013) 1.01

Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol (2013) 1.01

Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies. J Neurol (2013) 0.99

Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete? Neuroradiology (2011) 0.95

Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study. BMC Neurol (2013) 0.94

Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol (2014) 0.94

The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Int J Mol Sci (2016) 0.93

Neuromyelitis optica - an update: 2007-2009. Ann Indian Acad Neurol (2009) 0.92

Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices. Curr Neuropharmacol (2011) 0.91

Optic neuritis in neuromyelitis optica. Prog Retin Eye Res (2013) 0.90

Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int (2012) 0.90

Viruses and multiple sclerosis. Neuroscientist (2011) 0.90

Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol (2014) 0.87

Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibody. J Neurol Neurosurg Psychiatry (2007) 0.86

Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. J Neurol (2010) 0.85

Acquired demyelinating disorders of central nervous system: A pediatric cohort. Ann Indian Acad Neurol (2015) 0.85

Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One (2012) 0.85

Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84

Neuromyelitis optica spectrum disorders without and with autoimmune diseases. BMC Neurol (2014) 0.84

Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84

Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience. J Neurosci Rural Pract (2015) 0.83

Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. BMC Neurol (2014) 0.83

Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases. Front Immunol (2015) 0.83

Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler (2015) 0.82

Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology (2015) 0.81

Diagnosis of longitudinally extensive transverse myelitis. BMJ Case Rep (2011) 0.81

Anti-AQP(4) antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis. J Spinal Cord Med (2012) 0.81

The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. J Neurol (2010) 0.81

Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int (2011) 0.81

Immunotherapy of neuromyelitis optica. Autoimmune Dis (2013) 0.81

Isolated, relapsing and progressive demyelinating diseases of the central nervous system. J Neurol (2008) 0.80

Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute transverse myelitis. J Neurol (2013) 0.79

Neuromyelitis optica: atypical clinical and neuroradiological presentation. Neuroradiol J (2015) 0.78

Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature. BMC Neurol (2014) 0.78

Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord (2010) 0.77

Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma. BMC Ophthalmol (2014) 0.77

Review of Animal Models of Neuromyelitis Optica. Mult Scler Relat Disord (2012) 0.77

Differential diagnosis of white matter diseases in the tropics: An overview. Ann Indian Acad Neurol (2009) 0.77

Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica. Clin Dev Immunol (2013) 0.77

A diagnostic challenge in a young woman with intractable hiccups and vomiting: a case of neuromyelitis optica. J Community Hosp Intern Med Perspect (2015) 0.77

Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res (2017) 0.75

The Clinical Characteristics of Primary Sjogren's Syndrome With Neuromyelitis Optica Spectrum Disorder in China: A STROBE-Compliant Article. Medicine (Baltimore) (2015) 0.75

Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. AJNR Am J Neuroradiol (2017) 0.75

Neuromyelitis optica spectrum disease with positive autoimmune indices: a case report and review of the literature. Case Rep Med (2011) 0.75

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm (2016) 0.75

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. J Med Case Rep (2014) 0.75

The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol (2016) 0.75

Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica. Asian J Transfus Sci (2017) 0.75

What's new in neuromyelitis optica? A short review for the clinical neurologist. J Neurol (2017) 0.75

Recurrent Longitudinally Extensive Myelitis and Aquaporin-4 Seronegativity - The Expanding Spectrum of Neuromyelitis Optica. J Clin Diagn Res (2017) 0.75

Articles by these authors

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18

The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39

Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50

Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28

The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23

Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95

The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain (2009) 3.84

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain (2003) 3.39

Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26

Natural history of multiple sclerosis: a unifying concept. Brain (2006) 2.96

Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol (2012) 2.95

Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91

Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80

Gray matter involvement in multiple sclerosis. Neurology (2007) 2.75

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68

Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67

[(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc (2013) 2.64

Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A (2008) 2.57

Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49

Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46

Age at disability milestones in multiple sclerosis. Brain (2006) 2.37

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34

Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29

Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc (2004) 2.29

Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26

Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26

Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12

Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11

Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10

Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc (2003) 2.09

Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07

Experimental autoimmune autonomic neuropathy. J Neurophysiol (2003) 2.02

Do not treat from CIS onset: evaluate disease course and prognosis first--yes. Mult Scler (2012) 2.01

Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology (2012) 2.00

The spectrum of autoimmune autonomic neuropathies. Ann Neurol (2003) 1.93

Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89

Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc (2010) 1.85

Demyelination versus remyelination in progressive multiple sclerosis. Brain (2010) 1.82

Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol (2003) 1.79

Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci (2004) 1.78

Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol (2013) 1.78

Sleep manifestations of voltage-gated potassium channel complex autoimmunity. Arch Neurol (2011) 1.77

An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol (2009) 1.73

Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol (2008) 1.72

Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues. Lab Invest (2008) 1.67

Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61

Paraneoplastic jaw dystonia and laryngospasm with antineuronal nuclear autoantibody type 2 (anti-Ri). Arch Neurol (2010) 1.60

Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 1.59

Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol (2009) 1.55

Pathology of demyelinating diseases. Annu Rev Pathol (2012) 1.52

Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol (2005) 1.51

Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49